Clinical observation of treatment with recombinant human thrombopoietin on chemotherapy - induced thrombocytopenia in patients with hematological malignancies

Abstract

Objective To evaluate the safety and effectiveness of rhTPO on the treatment of chemotherapy - induced thrombocytopenia in patients with hematological malignancies. Methods Twelve leukemia and lymphoma patients with platelet count ≤20 × 109/L after chemotherapy were enrolled in the current study. They received two courses of chemotherapy with identical regimen and dosage. The first course was used as self - control. In the second course, rhTPO was subcutaneously administered at a dosage of 15 000 U/d for 8 - 14 days (until the platelet count ≥75× 109/L) when platelet count ≤50 × 109/L. Laboratory tests included blood routine and urine routine, serum biochemisty, blood coagulation tests. Results The mean minimal platelet count was( 11 ±4) × 109/L in the treatment goup versus(9.4 ±2.9) ×109/L in the control group, the difference was no significant (P ＞0.05). The duration of patients with platelet count ＜20 × 10 9/L was(7. 6 ±2. 0)d in the treatment group and(8. 7 ± 2. 2)d in the control group, the difference was significant (P ＜0.05). The mean maximal platelet count in patients' recovery period was(253 ±86) × 109/L and( 178 ±53) × 109/L respectively, the difference was significant (P ＜0.05). Platelet transfusion was(21.7 ±3.9)U in the treatment group and(24.2 ± 5.1)U in the control group, the difference was nor significant (P ＞0. 05 ). No severe side - effect was observed in the treatment group. Conclusions rhTPO could reduce the duration of chemotherapy - induced thrombocytopenia in patients with hematological malignancies and elevate the platelet count and without severe side - effect. Key words: Recombinant human thrombopoietin;  Leukemia;  Lymphoma;  Thrombocytopenia